Literature DB >> 8952579

Inherited forms of mineralocorticoid hypertension.

P C White1.   

Abstract

Aldosterone, the most important mineralocorticoid, regulates electrolyte excretion and intravascular volume mainly through its effects on renal distal convoluted tubules and cortical collecting ducts. Excess secretion of aldosterone or other mineralocorticoids or abnormal sensitivity to mineralocorticoids may result in hypertension, suppressed plasma renin activity, and hypokalemia. Such conditions often have a genetic basis, and studies of these conditions have provided valuable insights into the normal and abnormal physiology of mineralocorticoid action. Deficiencies of steroid 11 beta-hydroxylase or 17 alpha-hydroxylase are types of congenital adrenal hyperplasia, the autosomal recessive inability to synthesize cortisol. These two defects often cause hypertension because of overproduction of cortisol precursors that are, or are metabolized to, mineralocorticoid agonists. These disorders result from mutations in the CYP11B1 and CYP17 genes encoding the corresponding enzymes. Glucocorticoid-suppressible hyperaldosteronism is an autosomal dominant form of hypertension in which aldosterone secretion is abnormally regulated by corticotropin. It is caused by recombinations between linked genes encoding closely related isozymes, 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2), generating a dysregulated chimeric gene with aldosterone synthase activity. Apparent mineralocorticoid excess is a loss of functional ligand specificity of the mineralocorticoid receptor caused by a deficiency of the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase, an enzyme that normally metabolizes cortisol to cortisone to prevent cortisol from occupying the receptor. This autosomal recessive form of severe hypertension results from mutations in the HSD11K (HSD11B2) gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952579     DOI: 10.1161/01.hyp.28.6.927

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

1.  Steroidogenesis and CYP enzymes.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2001-10       Impact factor: 4.599

Review 2.  Cardiac genes and gene databases for cardiovascular disease genetics.

Authors:  K T Tan; A Dempsey; C C Liew
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

3.  Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension.

Authors:  Maricarmen Malagon-Rogers
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

Review 4.  Congenital adrenal hyperplasia causing hypertension: an illustrative review.

Authors:  Laura Hinz; Daniele Pacaud; Gregory Kline
Journal:  J Hum Hypertens       Date:  2017-12-18       Impact factor: 3.012

Review 5.  The epithelial sodium channel in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 6.  Genetics of hypertension. Therapeutic implications.

Authors:  S O'Byrne; M Caulfield
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

7.  Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up.

Authors:  Wael A Seliem; Michael C Falk; Bruce Shadbolt; Alison L Kent
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

Review 8.  Aldosterone and the risk of hypertension.

Authors:  Vanessa Xanthakis; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

Review 9.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

10.  Genetics of hypertension: discoveries from the bench to human populations.

Authors:  Nora Franceschini; Thu H Le
Journal:  Am J Physiol Renal Physiol       Date:  2013-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.